Challenges of evaluating the cardiac effects of anticancer agents

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 3871-3874

  Bates, Susan E ^a   Rosing, Douglas R ^b   Fojo, Tito ^a   Piekarz, Richard L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEPSIPEPTIDE; DOXORUBICIN; FR 901228; GRANISETRON; HISTONE DEACETYLASE INHIBITOR; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; IDARUBICIN; INTERFERON; INTERLEUKIN 2; LBH 589B; METHOTREXATE; METOPROLOL; OCTREOTIDE; ONDANSETRON; PACLITAXEL; SEROTONIN 3 ANTAGONIST; TERFENADINE; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT;

ADJUVANT CHEMOTHERAPY; BLADDER DISEASE; CANCER RESEARCH; CARCINOID SYNDROME; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; ECG ABNORMALITY; EDITORIAL; HEART MUSCLE INJURY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; METASTASIS; MUCOSA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SUDDEN DEATH; T WAVE INVERSION; TACHYCARDIA; TORSADE DES POINTES;

ANTINEOPLASTIC AGENTS; HEART; HEART DISEASES; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 33746080897     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1017     Document Type: Editorial

References (27)

1. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12:3997-4003.
2. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263-86.
3. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial fort-cell lymphoma. Clin Cancer Res 2006;12:3762-72.
4. van der Horst-Schrivers AN, Wymenga AN, Links TP, Willemse PH, Kema IP, de Vries EG. Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology 2004;80:28-32.
5. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973;32:1-8.
6. Wortman JE, Lucas VS, Jr., Schuster E, Thiele D, Logue GL. Sudden death during doxorubicin administration. Cancer 1979;44:1588-91.
7. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern CooperativeOncology Group. Cancer 1993;72:2457-60.
8. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704-12.
9. Vogl SE, Zaravinos T, Kaplan BH. Toxicity of cis-diamminedichloroplatinum II given in a two-hour out-patient regimen of diuresis and hydration. Cancer 1980;45:11-5.
10. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991;99:557-61.
11. Shulman KL, Stadler WM, Vogelzang NJ. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Urology 1996;47:194-7.
12. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001;98:266-71.
13. Spector PS. Diagnosis and management of sudden cardiac death. Heart 2005;91:408-13.
14. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007-12.
15. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
16. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-88.
17. Beck J, Fischer T, George D, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of oral LBH589B: a novel histone deacetylase inhibitor [abstract 3148]. Proc Amer Soc Clin Oncol 2005;23.
18. Fischer T, Patnaik A, Bhalla K, et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies [abstract 3106]. Proc Amer Soc Clin Oncol 2005;23.
19. Rowinsky EK, de Bono J, Deangelo DJ, et al. Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies [abstract 3131]. Proc Amer Soc Clin Oncol 2005;23.
20. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003;45:415-27.
21. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
22. Gralla R, Lichinitser M, Van DerVegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7.
23. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-82.
24. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8.
25. Duvic M, Talpur R, Zhang C, Goy A, Rlchon V, Frankel SR. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy [abstract 3326]. Proc Amer Soc Clin Oncol 2005;23.
26. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
27. Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 2006;92:316-20.